Immediate Impact
2 from Science/Nature 58 standout
Citing Papers
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
The senescence-associated secretory phenotype and its physiological and pathological implications
2024 Standout
Works of Mark Galan being referenced
Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars
2023
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Mark Galan | 188 | 23 | 8 | 174 | 80 | 23 | 396 | |
| Francis D. Speer | 149 | 34 | 2 | 75 | 85 | 30 | 440 | |
| Claudia Arce-Salinas | 224 | 84 | 4 | 169 | 135 | 23 | 422 | |
| Paul Carroll | 135 | 37 | 140 | 107 | 25 | 410 | ||
| İbrahim Petekkaya | 253 | 29 | 3 | 118 | 107 | 25 | 372 | |
| V. K. Vaitkevicius | 163 | 48 | 45 | 49 | 87 | 22 | 436 | |
| A Saragoni | 165 | 12 | 97 | 79 | 23 | 446 | ||
| Daniel Torres‐Moreno | 109 | 46 | 14 | 58 | 112 | 24 | 389 | |
| A. Michelotti | 199 | 34 | 13 | 100 | 64 | 15 | 344 | |
| Fredrika Killander | 191 | 18 | 3 | 242 | 45 | 25 | 394 | |
| Greenspan Em | 154 | 49 | 21 | 66 | 68 | 23 | 397 |
All Works
Login with ORCID to disown or claim papers
Loading papers...